Skip to main content

Table 1 Summary of Patient and Study Characteristics of 209 Studies Included in our Systematic Review

From: Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis

Characteristic

Number of Studies (%)

Age, mean (years)

  < 70

7 (3.3)

 70–79·9

116 (55.5)

  ≥ 80

68 (32.5)

 Not Reported

18 (8.6)

% Women

 0–49

31 (14.8)

 50–100

165 (78.9)

 Not Reported

13 (6.2)

Type of Dementia

 Multiple (e.g. AD + VaD)

50 (23.9)

 AD

110 (52.6)

 VaD

10 (4.8)

 Othera

9 (4.3)

 Not Reported

30 (14.4)

Severity of Dementia

 Mild

2 (1)

 Mild/Moderate

67 (32.1)

 Mild/Moderate/Severe

36 (17.2)

 Moderate

5 (2.4)

 Moderate/Severe

24 (11.5)

 Severe

6 (2.9)

 Not Reported

69 (33)

Study Design

 RCT

148 (70.8)

 Cohort Study

52 (24.9)

 Case-Control Study

5 (2.4)

 Pairwise Meta-Analysis of RCTs

2 (1)

 Other Non-Randomized Study

2 (1)

Setting

 Clinic/Community

65 (31.1)

 Hospital

7 (3.3)

 Nursing home/Assisted Living

45 (21.5)

 Multiple Settings

22 (10.5)

 Not Reported

70 (33.5)

Sample Size (No. of patients)

  < 200

64 (30.6)

 201–500

63 (30.1)

  > 500

81 (38.8)

 Not Reported

1 (0.5)

Duration of Intervention, weeks

  < 13

65 (31.1)

 13–30

78 (37.3)

  > 30

57 (27.2)

 Not Reported

9 (4.3)

  1. Abbreviations: AD Alzheimer’s dementia, % percentage, RCT randomized trial, VaD vascular dementia
  2. aOther includes Lewy body dementia, Parkinson’s disease dementia, and frontotemporal dementia